Drug Patents owned by United Therap

1. List of Orenitram drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9050311 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US7417070 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2026

(3 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US8497393 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(5 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(5 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9422223 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US8252839 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US9278901 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US7544713 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Jul, 2024

(1 year, 5 months from now)

US9393203 UNITED THERAP Osmotic drug delivery system
Apr, 2026

(3 years from now)

US8410169 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Feb, 2030

(7 years from now)

US8349892 UNITED THERAP Solid formulations of prostacyclin analogs
Jan, 2031

(7 years from now)

US8747897 UNITED THERAP Osmotic drug delivery system
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
Orphan Drug Exclusivity (ODE) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil; A method of treating pulmonary hypertension and pulmonary arterial hypertension by administering an oral osmotic pharmaceutical dosage form; A method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's patent expiration?
More Information on Dosage

2. List of Remodulin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(5 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(5 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9199908 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
May, 2024

(1 year, 3 months from now)

US10076505 UNITED THERAP Inhalation formulations of Treprostinil
Dec, 2024

(1 year, 10 months from now)

US9713599 UNITED THERAP Parenteral formulations of treprostinil
Dec, 2024

(1 year, 10 months from now)

US10695308 UNITED THERAP Inhalation formulations of treprostinil
Dec, 2024

(1 year, 10 months from now)

US8653137 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(5 years from now)

US8658694 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Sep, 2028

(5 years from now)

US7999007 UNITED THERAP Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Mar, 2029

(6 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 21 May, 2002

Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer; A method of treating a human patient suffering from pulmonary hypertension; Administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration

Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS

How can I launch a generic of REMODULIN before it's patent expiration?
More Information on Dosage

3. List of Tyvaso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(5 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(5 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10376525 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US9339507 UNITED THERAP Treprostinil administration by inhalation
Mar, 2028

(5 years from now)

US9358240 UNITED THERAP Treprostinil administration by inhalation
May, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 31, 2024

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 30 July, 2009

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: SOLUTION;INHALATION

How can I launch a generic of TYVASO before it's patent expiration?
More Information on Dosage

4. List of Tyvaso Dpi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9593066 UNITED THERAP Process to prepare treprostinil, the active ingredient in remodulin®
Dec, 2028

(5 years from now)

US9604901 UNITED THERAP Process to prepare treprostinil, the active ingredient in Remodulin®
Dec, 2028

(5 years from now)

CN103274926A UNITED THERAP Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN103274926B UNITED THERAP An Improved Method For Preparing Active Components In The Curved Remodulin
Dec, 2028

(5 years from now)

CN101903324A UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

CN101903324B UNITED THERAP A Kind Of Preparation Of Active Composition In Remodulin Curved Latanoprost Is Improved Method
Dec, 2028

(5 years from now)

IN201003640P4 UNITED THERAP An Improved Process To Prepare Treprostinil,The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

IN287697B UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin
Dec, 2028

(5 years from now)

EP2252570A1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

EP2252570B1 UNITED THERAP An Improved Process To Prepare Treprostinil, The Active Ingredient In Remodulin ®
Dec, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(2 years from now)

US10716793 UNITED THERAP Treprostinil administration by inhalation
May, 2027

(4 years from now)

US10772883 UNITED THERAP Diketopiperazine microparticles with defined specific surface areas
Jun, 2030

(7 years from now)

US10421729 UNITED THERAP Microcrystalline diketopiperazine compositions and methods
Apr, 2035

(12 years from now)

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device

Dosage: POWDER;INHALATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in